NCT02890355 2026-03-05
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
25 trialsNCT03785210 2026-02-23
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01064622 2024-11-19
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03801915 2023-03-21
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT04327986 2022-05-18
Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02810418 2022-03-15
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00617708 2022-02-08
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01445327 2022-02-01
Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers
National Institutes of Health Clinical Center (CC)
Terminated
NCT02311361 2021-04-20
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03300843 2019-12-13
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01294358 2019-11-13
Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00416793 2019-10-31
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01583686 2019-10-14
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01362790 2019-06-06
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00735917 2019-04-02
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01280058 2018-03-09
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00383760 2017-10-20
Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients
National Cancer Institute (NCI)
Phase 2 Completed
NCT00474812 2015-05-05
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00114244 2015-01-14
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01232829 2014-11-26
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00482625 2014-10-16
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00577889 2014-07-25
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00331682 2014-05-28
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00305877 2014-05-21
Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00091026 2014-05-15
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed